Gilead's idelalisib shows promise against leukemia

10/9/2013 | Reuters

Gilead Sciences said a late-stage trial of its experimental drug idelalisib was halted early after a data-monitoring panel found that the drug significantly improved progression-free survival in patients with chronic lymphocytic leukemia who can't receive chemotherapy. Gilead said it is discussing the results of the study and a possible regulatory application with the FDA. In September, the firm submitted the drug for FDA approval as a treatment for non-Hodgkin lymphoma.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ